ABIONYX PHARMA overview

Regulatory News: ABIONYX Pharma, (FR0012616852 - ABNX - PEA PME eligible) , a new generation biotech company dedicated to the discovery and development of innovative therapies based on the world's only natural recombinant ApoA-I, today provided an update on its business and cash position for the 1 st half to June 30, 2023. The company recorded consolidated half-year sales of €2.1 million, after elimination of intra-group transactions. IRIS Pharma recorded half-year sales of €2.4 million. At...

Regulatory News: ABIONYX Pharma (Paris:ABNX): Market: Euronext Paris, Compartment C ISIN code: FR0012616852 Date Number of shares outstanding Total voting rights Total gross (1) Total net (2) July 31, 2023 28,439,382 28,439,382 28,171,969 (1) The total number of gross (or “theoretical”) voting rights is used as the basis for calculating threshold crossings. In accordance with Article 223-11 of the AMF General Regulations, this number is calculated on the basis of all shares to which voting...

Regulatory News: ABIONYX Pharma, (FR0012616852 - ABNX - PEA PME eligible) , a new generation biotech company dedicated to the discovery and development of innovative therapies based on the world's only natural recombinant ApoA-I, announces the successful completion of a second batch for the GMP (Good Manufacturing Practice) industrial biomanufacturing of CER-001 using an innovative and robust method. Demonstrated success for the industrial biomanufacturing of CER-001, one of the most advanced...

Regulatory News: ABIONYX Pharma, (FR0012616852 - ABNX - PEA PME eligible) (Paris:ABNX), a new generation biotech company dedicated to the discovery and development of innovative therapies based on the world's only natural recombinant ApoA-I, today announces the appointment of Laurent Guerci as Chief Digital & Innovation Officer. Agricultural engineer and graduate of the CPA (Executive MBA), Laurent Guerci has spent his entire career in information systems, first as the founding director of a...

Regulatory News: ABIONYX Pharma, (FR0012616852 - ABNX - PEA PME eligible) , a new generation biotech company dedicated to the discovery and development of innovative therapies based on the world's only natural recombinant ApoA-I, announces that the company has been granted a new Compassionate Access Authorization (CAA) in Europe for CER-001 in the rare, untreated kidney disease LCAT Deficiency. This is the fourth patient suffering from LCAT deficiency to be granted Compassionate Access to...

Regulatory News: ABIONYX Pharma (Paris:ABNX): Market: Euronext Paris, Compartment C ISIN code: FR0012616852 Date Number of shares outstanding Total voting rights Total gross (1) Total net (2) June 30, 2023 28,439,382 28,439,382 28,165,338 The total number of gross (or “theoretical”) voting rights is used as the basis for calculating threshold crossings. In accordance with Article 223-11 of the AMF General Regulations, this number is calculated on the basis of all shares to which voting...

ABIONYX Pharma, (FR0012616852 - ABNX - PEA PME eligible) , a new generation biotech company dedicated to the discovery and development of innovative therapies based, announces that all resolutions presented at its Combined General Meeting were unanimously approved. Among the resolutions adopted were the renewal of the mandates of Laura A. Coruzzi, Karen Noel and Cyrille Tupin, Chief Executive Officer of ABIONYX Pharma, for a 3-year term. Shareholders also approved the renewal of the share...

Regulatory News: ABIONYX Pharma (Paris:ABNX): Market: Euronext Paris, Compartment C ISIN code: FR0012616852 Date Number of shares outstanding Total voting rights Total gross (1) Total net (2) May 31, 2023 28,439,382 28,439,382 28,176,219 The total number of gross (or “theoretical”) voting rights is used as the basis for calculating threshold crossings. In accordance with Article 223-11 of the AMF General Regulations, this number is calculated on the basis of all shares to which voting rights...